Skip to main navigation Skip to search Skip to main content

Current status of health systems financing and oversight for end-stage kidney disease care: A cross-sectional global survey

  • Emily Yeung*
  • , A. K. Bello
  • , Adeera Levin
  • , Meaghan Lunney
  • , Mohamed A. Osman
  • , Feng Ye
  • , Gloria Ashuntantang
  • , Ezequiel Bellorin-Font
  • , Mohammed Benghanem Gharbi
  • , Sara Davison
  • , Mohammad Ghnaimat
  • , Paul Harden
  • , Vivekanand Jha
  • , Kamyar Kalantar-Zadeh
  • , Peter Kerr
  • , Scott Klarenbach
  • , Csaba Kovesdy
  • , Valerie Luyckx
  • , Brendon Neuen
  • , Donal O'Donoghue
  • Shahrzad Ossareh, Jeffrey Perl, Harun Ur Rashid, Eric Rondeau, Emily See, Syed Saad, Laura Sola, Irma Tchokhonelidze, Vladimir Tesar, Kriang Tungsanga, Rumeyza Turan Kazancioglu, Angela Yee Moon Wang, Natasha Wiebe, Chih Wei Yang, Alexander Zemchenkov, Minhui Zhao, Kitty J. Jager, Fergus Caskey, Vlado Perkovic, Kailash Jindal, Ikechi G. Okpechi, Marcello Tonelli, John Feehally, David C.H. Harris, David Johnson
*Corresponding author for this work
  • Monash Health
  • University of Alberta
  • University of British Columbia
  • University of Calgary
  • Université de Yaoundé I
  • Saint Louis University
  • University of Hassan II Casablanca
  • The Specialty Hospital
  • Oxford University Hospitals NHS Foundation Trust
  • The George Institute for Global Health
  • University of California at Irvine
  • Monash University
  • Department of Veterans Affairs
  • University of Zurich
  • Northern Care Alliance NHS Group
  • University of Manchester
  • Iran University of Medical Sciences
  • University of Toronto
  • Kidney Foundation Hospital and Research Institute
  • Assistance publique – Hôpitaux de Paris
  • University of Melbourne
  • Dialysis Unit
  • Tbilisi State Medical University
  • Charles University
  • Chulalongkorn University
  • Bhumirajanagarindra Kidney Institute
  • Bezmialem Vakif University
  • The University of Hong Kong
  • North-Western State Medical University named after I.I. Mechnikov
  • Peking University
  • University of Amsterdam
  • University of Bristol
  • University of Cape Town
  • University of Leicester
  • Westmead Millennium Institute for Medical Research
  • University of Queensland
  • Princess Alexandra Hospital

Research output: Contribution to journalJournal Article peer-review

45 Scopus citations

Abstract

The Global Kidney Health Atlas (GKHA) is a multinational, cross-sectional survey designed to assess the current capacity for kidney care across all world regions. The 2017 GKHA involved 125 countries and identified significant gaps in oversight, funding and infrastructure to support care for patients with kidney disease, especially in lower-middle-income countries. Here, we report results from the survey for the second iteration of the GKHA conducted in 2018, which included specific questions about health financing and oversight of end-stage kidney disease (ESKD) care worldwide. A cross-sectional global survey. Key stakeholders from 182 countries were invited to participate. Of those, stakeholders from 160 countries participated and were included. Primary outcomes included cost of kidney replacement therapy (KRT), funding for dialysis and transplantation, funding for conservative kidney management, extent of universal health coverage, out-of-pocket costs for KRT, within-country variability in ESKD care delivery and oversight systems for ESKD care. Outcomes were determined from a combination of desk research and input from key stakeholders in participating countries. 160 countries (covering 98% of the world’s population) responded to the survey. Economic factors were identified as the top barrier to optimal ESKD care in 99 countries (64%). Full public funding for KRT was more common than for conservative kidney management (43% vs 28%). Among countries that provided at least some public coverage for KRT, 75% covered all citizens. Within-country variation in ESKD care delivery was reported in 40% of countries. Oversight of ESKD care was present in all high-income countries but was absent in 13% of low-income, 3% of lower-middle-income, and 10% of upper-middle-income countries. Significant gaps and variability exist in the public funding and oversight of ESKD care in many countries, particularly for those in low-income and lower-middle-income countries.

Original languageEnglish
Article numbere047245
JournalBMJ Open
Volume11
Issue number7
DOIs
StatePublished - 09 07 2021

Bibliographical note

Publisher Copyright:
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being
  2. SDG 9 - Industry, Innovation, and Infrastructure
    SDG 9 Industry, Innovation, and Infrastructure
  3. SDG 10 - Reduced Inequalities
    SDG 10 Reduced Inequalities

Keywords

  • chronic renal failure
  • dialysis
  • end stage renal failure
  • epidemiology
  • health economics
  • organisation of health services

Fingerprint

Dive into the research topics of 'Current status of health systems financing and oversight for end-stage kidney disease care: A cross-sectional global survey'. Together they form a unique fingerprint.

Cite this